Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Moodys
Dow
McKesson

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Lasmiditan

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Lasmiditan?

Lasmiditan is an investigational drug.

There have been 25 clinical trials for Lasmiditan. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2015.

The most common disease conditions in clinical trials are Migraine Disorders, Substance-Related Disorders, and Renal Insufficiency. The leading clinical trial sponsors are Eli Lilly and Company, CoLucid Pharmaceuticals, and Algorithme Pharma Inc.

There are five US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for Lasmiditan
TitleSponsorPhase
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in KoreanIlDong Pharmaceutical Co LtdPhase 3
A Study of Lasmiditan in Healthy Chinese ParticipantsEli Lilly and CompanyPhase 1
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With MigraineEli Lilly and CompanyPhase 1

See all Lasmiditan clinical trials

Clinical Trial Summary for Lasmiditan

Top disease conditions for Lasmiditan
Top clinical trial sponsors for Lasmiditan

See all Lasmiditan clinical trials

US Patents for Lasmiditan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lasmiditan   Start Trial Pyridinoylpiperidines as 5-HT.sub.1F agonists Eli Lilly and Company (Indianapolis, IN)   Start Trial
Lasmiditan   Start Trial Pyridinoylpiperidines as 5-HT.sub.1F agonists Eli Lilly and Company (Indianapolis, IN)   Start Trial
Lasmiditan   Start Trial Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists Colucid Pharmaceuticals, Inc. (Durham, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Mallinckrodt
Merck
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.